Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Defining Polysaccharide Antibody Deficiency: Measurement of Anti-Pneumococcal Antibodies and Anti-Salmonella typhi Antibodies in a Cohort of Patients with Recurrent Infections.

Bucciol G, Schaballie H, Schrijvers R, Bosch B, Proesmans M, De Boeck K, Boon M, Vermeulen F, Lorent N, Dillaerts D, Kantsø B, Jørgensen CS, Emonds MP, Bossuyt X, Moens L, Meyts I.

J Clin Immunol. 2019 Nov 8. doi: 10.1007/s10875-019-00691-8. [Epub ahead of print]

PMID:
31705452
2.

Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.

De Vriese AS, Caluwé R, Pyfferoen L, De Bacquer D, De Boeck K, Delanote J, De Surgeloose D, Van Hoenacker P, Van Vlem B, Verbeke F.

J Am Soc Nephrol. 2019 Nov 8. pii: ASN.2019060579. doi: 10.1681/ASN.2019060579. [Epub ahead of print]

PMID:
31704740
3.

Isolation of Enterobacteriaceae in airway samples is associated with worse outcome in preschool children with cystic fibrosis.

Vermeulen F, Proesmans M, Vermaelen M, Boon M, De Boeck K.

J Cyst Fibros. 2019 Nov 2. pii: S1569-1993(19)30934-8. doi: 10.1016/j.jcf.2019.10.019. [Epub ahead of print]

PMID:
31690526
4.

Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.

Cuyx S, De Boeck K.

Semin Respir Crit Care Med. 2019 Oct 28. doi: 10.1055/s-0039-1696664. [Epub ahead of print]

PMID:
31659727
5.

Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis-data from the European cystic fibrosis society patient registry.

Hatziagorou E, Orenti A, Drevinek P, Kashirskaya N, Mei-Zahav M, De Boeck K; ECFSPR. Electronic address: ECFS-Patient.Registry@uz.kuleuven.ac.be; ECFSPR.

J Cyst Fibros. 2019 Sep 3. pii: S1569-1993(19)30838-0. doi: 10.1016/j.jcf.2019.08.006. [Epub ahead of print]

PMID:
31492646
6.

Lung function evolution in children with old and new type bronchopulmonary dysplasia: a retrospective cohort analysis.

Cardoen F, Vermeulen F, Proesmans M, Moens M, De Boeck K.

Eur J Pediatr. 2019 Dec;178(12):1859-1866. doi: 10.1007/s00431-019-03453-1. Epub 2019 Sep 5.

PMID:
31486896
7.

Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing.

Maule G, Casini A, Montagna C, Ramalho AS, De Boeck K, Debyser Z, Carlon MS, Petris G, Cereseto A.

Nat Commun. 2019 Aug 7;10(1):3556. doi: 10.1038/s41467-019-11454-9.

8.

Nasal potential difference in suspected cystic fibrosis patients with 5T polymorphism.

Aalbers BL, Yaakov Y, Derichs N, Simmonds NJ, De Wachter E, Melotti P, De Boeck K, Leal T, Tümmler B, Wilschanski M, Bronsveld I.

J Cyst Fibros. 2019 Jul 19. pii: S1569-1993(19)30822-7. doi: 10.1016/j.jcf.2019.07.001. [Epub ahead of print]

PMID:
31331863
9.

Theranostics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutations.

Amaral MD, de Boeck K; ECFS Strategic Planning Task Force on ‘Speeding up access to new drugs for CF’.

J Cyst Fibros. 2019 Sep;18(5):685-692. doi: 10.1016/j.jcf.2019.06.010. Epub 2019 Jul 17.

PMID:
31326274
10.

Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery.

Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T; European CF Society (ECFS) Strategic Planning Task Force on ‘Speeding up access to new 4 drugs for CF’, Amaral MD, de Boeck K, Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T.

J Cyst Fibros. 2019 Sep;18(5):677-684. doi: 10.1016/j.jcf.2019.06.011. Epub 2019 Jul 11.

PMID:
31303382
11.

A Method for Comprehensive Proteomic Analysis of Human Faecal Samples to Investigate Gut Dysbiosis in Patients with Cystic Fibrosis.

Debyser G, Aerts M, Van Hecke P, Mesuere B, Duytschaever G, Dawyndt P, De Boeck K, Vandamme P, Devreese B.

Adv Exp Med Biol. 2019;1073:137-160. doi: 10.1007/978-3-030-12298-0_6.

PMID:
31236842
12.

Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis.

Drevinek P, Pressler T, Cipolli M, De Boeck K, Schwarz C, Bouisset F, Boff M, Henig N, Paquette-Lamontagne N, Montgomery S, Perquin J, Tomkinson N, den Hollander W, Elborn JS.

J Cyst Fibros. 2019 Jun 7. pii: S1569-1993(19)30766-0. doi: 10.1016/j.jcf.2019.05.014. [Epub ahead of print]

13.

CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials.

Bell SC, Barry PJ, De Boeck K, Drevinek P, Elborn JS, Plant BJ, Minić P, Van Braeckel E, Verhulst S, Muller K, Kanters D, Bellaire S, de Kock H, Geller DE, Conrath K, Van de Steen O, van der Ent K.

J Cyst Fibros. 2019 Sep;18(5):700-707. doi: 10.1016/j.jcf.2019.04.014. Epub 2019 May 3.

14.

The Relative Contribution of Food Groups to Macronutrient Intake in Children with Cystic Fibrosis: A European Multicenter Assessment.

Calvo-Lerma J, Hulst J, Boon M, Martins T, Ruperto M, Colombo C, Fornés-Ferrer V, Woodcock S, Claes I, Asseiceira I, Garriga M, Bulfamante A, Masip E, Walet S, Crespo P, Valmarana L, Martínez-Barona S, Pereira L, de Boeck K, Ribes-Koninckx C.

J Acad Nutr Diet. 2019 Aug;119(8):1305-1319. doi: 10.1016/j.jand.2019.01.003. Epub 2019 Mar 9. Erratum in: J Acad Nutr Diet. 2019 Nov;119(11):1957.

PMID:
30862484
15.

Clinical validation of an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy through a prospective interventional study in paediatric patients with Cystic Fibrosis.

Calvo-Lerma J, Hulst J, Boon M, Colombo C, Masip E, Ruperto M, Fornés-Ferrer V, van der Wiel E, Claes I, Garriga M, Roca M, Crespo-Escobar P, Bulfamante A, Woodcock S, Martínez-Barona S, Andrés A, de Boeck K, Ribes-Koninckx C; MyCyFAPP project.

PLoS One. 2019 Mar 12;14(3):e0213216. doi: 10.1371/journal.pone.0213216. eCollection 2019.

16.

Predictors of Reduced Survival for Adult-diagnosed Cystic Fibrosis: Older Age at Diagnosis, a Substitute for Older Age?

Fieuws S, Hatziagorou E, De Boeck K.

Ann Am Thorac Soc. 2019 May;16(5):644. doi: 10.1513/AnnalsATS.201812-896LE. No abstract available.

17.

Optimisation of children z-score calculation based on new statistical techniques.

Martinez-Millana A, Hulst JM, Boon M, Witters P, Fernandez-Llatas C, Asseiceira I, Calvo-Lerma J, Basagoiti I, Traver V, De Boeck K, Ribes-Koninckx C.

PLoS One. 2018 Dec 20;13(12):e0208362. doi: 10.1371/journal.pone.0208362. eCollection 2018.

18.

Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.

Sermet-Gaudelus I, Clancy JP, Nichols DP, Nick JA, De Boeck K, Solomon GM, Mall MA, Bolognese J, Bouisset F, den Hollander W, Paquette-Lamontagne N, Tomkinson N, Henig N, Elborn JS, Rowe SM.

J Cyst Fibros. 2019 Jul;18(4):536-542. doi: 10.1016/j.jcf.2018.10.015. Epub 2018 Nov 19.

19.

Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Ashkenazi M, Sity S, Sarouk I, Bar Aluma BE, Dagan A, Bezalel Y, Bentur L, De Boeck K, Efrati O.

J Asthma Allergy. 2018 Jun 19;11:101-107. doi: 10.2147/JAA.S156049. eCollection 2018. Erratum in: J Asthma Allergy. 2018 Sep 13;11:245.

20.

No easy road to better cystic fibrosis care in Eastern Europe?

De Boeck K, Fajac I.

J Cyst Fibros. 2018 Jul;17(4):423-424. doi: 10.1016/j.jcf.2018.05.007. Epub 2018 May 31. No abstract available.

PMID:
29859834
21.

Monocytes from patients with Primary Ciliary Dyskinesia show enhanced inflammatory properties and produce higher levels of pro-inflammatory cytokines.

Cockx M, Gouwy M, Ruytinx P, Lodewijckx I, Van Hout A, Knoops S, Pörtner N, Ronsse I, Vanbrabant L, Godding V, De Boeck K, Van Damme J, Boon M, Struyf S.

Sci Rep. 2017 Nov 7;7(1):14657. doi: 10.1038/s41598-017-15027-y.

22.

Neutrophils from Patients with Primary Ciliary Dyskinesia Display Reduced Chemotaxis to CXCR2 Ligands.

Cockx M, Gouwy M, Godding V, De Boeck K, Van Damme J, Boon M, Struyf S.

Front Immunol. 2017 Sep 22;8:1126. doi: 10.3389/fimmu.2017.01126. eCollection 2017.

23.

Where are we with transformational therapies for patients with cystic fibrosis?

De Boeck K, Davies JC.

Curr Opin Pharmacol. 2017 Jun;34:70-75. doi: 10.1016/j.coph.2017.09.005. Epub 2017 Oct 6. Review.

PMID:
28992608
24.

Real life practice of sweat testing in Europe.

Cirilli N, Southern KW, Buzzetti R, Barben J, Nährlich L, Munck A, Wilschanski M, De Boeck K, Derichs N; of the ECFS Diagnostic Network Working Group.

J Cyst Fibros. 2017 Sep 27. pii: S1569-1993(17)30881-0. doi: 10.1016/j.jcf.2017.09.002. [Epub ahead of print]

PMID:
28964647
25.

Clinical impact of Pseudomonas aeruginosa colonization in patients with Primary Ciliary Dyskinesia.

Cohen-Cymberknoh M, Weigert N, Gileles-Hillel A, Breuer O, Simanovsky N, Boon M, De Boeck K, Barbato A, Snijders D, Collura M, Pradal U, Blau H, Mussaffi H, Price M, Bentur L, Gur M, Aviram M, Picard E, Shteinberg M, Livnat G, Rivlin J, Hiller N, Shoseyov D, Amirav I, Kerem E.

Respir Med. 2017 Oct;131:241-246. doi: 10.1016/j.rmed.2017.08.028. Epub 2017 Sep 1.

PMID:
28947038
26.

The diagnosis of cystic fibrosis.

De Boeck K, Vermeulen F, Dupont L.

Presse Med. 2017 Jun;46(6 Pt 2):e97-e108. doi: 10.1016/j.lpm.2017.04.010. Epub 2017 May 31. Review.

PMID:
28576637
27.

Fifth Percentile Cutoff Values for Antipneumococcal Polysaccharide and Anti-Salmonella typhi Vi IgG Describe a Normal Polysaccharide Response.

Schaballie H, Bosch B, Schrijvers R, Proesmans M, De Boeck K, Boon MN, Vermeulen F, Lorent N, Dillaerts D, Frans G, Moens L, Derdelinckx I, Peetermans W, Kantsø B, Jørgensen CS, Emonds MP, Bossuyt X, Meyts I.

Front Immunol. 2017 May 12;8:546. doi: 10.3389/fimmu.2017.00546. eCollection 2017.

28.

Cystic fibrosis carriership and tuberculosis: hints toward an evolutionary selective advantage based on data from the Brazilian territory.

Bosch L, Bosch B, De Boeck K, Nawrot T, Meyts I, Vanneste D, Le Bourlegat CA, Croda J, da Silva Filho LVRF.

BMC Infect Dis. 2017 May 12;17(1):340. doi: 10.1186/s12879-017-2448-z.

29.

Biobanking: towards increased access of biomaterials in cystic fibrosis. Report on the pre-conference meeting to the 13th ECFS Basic Science Conference, Pisa, 30 March-2 April, 2016.

Beekman JM, Wang CM, Casati S, Tuggle KL, Gulmans VAM, Amaral M, De Boeck K.

J Cyst Fibros. 2017 Sep;16(5):616-621. doi: 10.1016/j.jcf.2017.04.009. Epub 2017 May 3. No abstract available.

30.

Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension.

Witters P, Libbrecht L, Roskams T, De Boeck K, Dupont L, Proesmans M, Vermeulen F, Maleux G, Monbaliu D, Pirenne J, Cassiman D.

J Cyst Fibros. 2017 Sep;16(5):e11-e13. doi: 10.1016/j.jcf.2017.03.006. Epub 2017 Mar 25. No abstract available.

31.

Nutritional status, nutrient intake and use of enzyme supplements in paediatric patients with Cystic Fibrosis; a European multicentre study with reference to current guidelines.

Calvo-Lerma J, Hulst JM, Asseiceira I, Claes I, Garriga M, Colombo C, Fornés V, Woodcock S, Martins T, Boon M, Ruperto M, Walet S, Speziali C, Witters P, Masip E, Barreto C, de Boeck K, Ribes-Koninckx C; MyCyFAPP Project.

J Cyst Fibros. 2017 Jul;16(4):510-518. doi: 10.1016/j.jcf.2017.03.005. Epub 2017 Mar 17.

32.

Innovative approach for self-management and social welfare of children with cystic fibrosis in Europe: development, validation and implementation of an mHealth tool (MyCyFAPP).

Calvo-Lerma J, Martinez-Jimenez CP, Lázaro-Ramos JP, Andrés A, Crespo-Escobar P, Stav E, Schauber C, Pannese L, Hulst JM, Suárez L, Colombo C, Barreto C, de Boeck K, Ribes-Koninckx C; MyCyFAPP.

BMJ Open. 2017 Mar 16;7(3):e014931. doi: 10.1136/bmjopen-2016-014931.

33.

Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial.

De Boeck K, Haarman E, Hull J, Lands LC, Moeller A, Munck A, Riethmüller J, Tiddens H, Volpi S, Leadbetter J, Charlton B, Malfroot A; DPM-CF-204 Study Group.

J Cyst Fibros. 2017 May;16(3):380-387. doi: 10.1016/j.jcf.2017.02.003. Epub 2017 Mar 1.

34.

Ethnicity impacts the cystic fibrosis diagnosis: A note of caution.

Bosch B, Bilton D, Sosnay P, Raraigh KS, Mak DYF, Ishiguro H, Gulmans V, Thomas M, Cuppens H, Amaral M, De Boeck K.

J Cyst Fibros. 2017 Jul;16(4):488-491. doi: 10.1016/j.jcf.2017.01.016. Epub 2017 Feb 21.

35.

[New tools in cystic fibrosis].

Dournes G, De Boeck K, Bui S, Vermeulen F, Ramalho A, Chateil JF, Laurent F, Fayon M.

Arch Pediatr. 2016 Dec;23(12S):12S39-12S46. doi: 10.1016/S0929-693X(17)30061-1. Review. French.

PMID:
28231892
36.

Diagnosis of Cystic Fibrosis in Nonscreened Populations.

Sosnay PR, White TB, Farrell PM, Ren CL, Derichs N, Howenstine MS, Nick JA, De Boeck K.

J Pediatr. 2017 Feb;181S:S52-S57.e2. doi: 10.1016/j.jpeds.2016.09.068.

PMID:
28129813
37.

Does newborn screening influence the young cystic fibrosis cohort included in national registries?

De Boeck K, Munck A, de Monestrol I, Gulmans V, Lemonnier L, Middleton PG, Wanyama S, Thomas M.

Eur Respir J. 2017 Jan 11;49(1). pii: 1600686. doi: 10.1183/13993003.00686-2016. Print 2017 Jan. No abstract available.

38.

Biological variability of the sweat chloride in diagnostic sweat tests: A retrospective analysis.

Vermeulen F, Lebecque P, De Boeck K, Leal T.

J Cyst Fibros. 2017 Jan;16(1):30-35. doi: 10.1016/j.jcf.2016.11.008. Epub 2016 Dec 22.

39.

New horizons for cystic fibrosis treatment.

Fajac I, De Boeck K.

Pharmacol Ther. 2017 Feb;170:205-211. doi: 10.1016/j.pharmthera.2016.11.009. Epub 2016 Dec 1. Review.

PMID:
27916649
40.

Equitable CF care as a basic human right.

De Boeck K, Kerem E.

J Cyst Fibros. 2016 Nov;15(6):703-704. doi: 10.1016/j.jcf.2016.09.006. Epub 2016 Oct 15. No abstract available.

41.

Year to year change in FEV1 in patients with cystic fibrosis and different mutation classes.

De Boeck K, Zolin A.

J Cyst Fibros. 2017 Mar;16(2):239-245. doi: 10.1016/j.jcf.2016.09.009. Epub 2016 Oct 11.

42.

Continuous alternating inhaled antibiotic therapy in CF: A single center retrospective analysis.

Van de Kerkhove C, Goeminne PC, Kicinski M, Nawrot TS, Lorent N, Van Bleyenbergh P, De Boeck K, Dupont LJ.

J Cyst Fibros. 2016 Nov;15(6):802-808. doi: 10.1016/j.jcf.2016.09.002. Epub 2016 Oct 5.

43.

A novel translational model for fetoscopic intratracheal delivery of nanoparticles in piglets.

Carlon MS, Engels AC, Bosch B, Joyeux L, Mori da Cunha MG, Vidović D, Debyser Z, De Boeck K, Neyrinck A, Deprest JA.

Prenat Diagn. 2016 Oct;36(10):926-934. doi: 10.1002/pd.4915. Epub 2016 Sep 18.

PMID:
27567969
44.

Classification of CFTR mutation classes - Authors' reply.

De Boeck K, Amaral MD.

Lancet Respir Med. 2016 Aug;4(8):e39. doi: 10.1016/S2213-2600(16)30189-8. Epub 2016 Jul 1. No abstract available.

PMID:
27377413
45.

Beyond pancreatic insufficiency and liver disease in cystic fibrosis.

Demeyer S, De Boeck K, Witters P, Cosaert K.

Eur J Pediatr. 2016 Jul;175(7):881-94. doi: 10.1007/s00431-016-2719-5. Epub 2016 Apr 7. Review.

PMID:
27055450
46.

Progress in therapies for cystic fibrosis.

De Boeck K, Amaral MD.

Lancet Respir Med. 2016 Aug;4(8):662-674. doi: 10.1016/S2213-2600(16)00023-0. Epub 2016 Apr 1. Review.

PMID:
27053340
47.

Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations.

Vermeulen F, Le Camus C, Davies JC, Bilton D, Milenković D, De Boeck K.

J Cyst Fibros. 2017 Jan;16(1):36-40. doi: 10.1016/j.jcf.2016.02.015. Epub 2016 Mar 17.

48.

The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials.

Caluwé R, Pyfferoen L, De Boeck K, De Vriese AS.

Clin Kidney J. 2016 Apr;9(2):273-9. doi: 10.1093/ckj/sfv146. Epub 2015 Dec 29.

49.

Disease-specific clinical trials networks: the example of cystic fibrosis.

De Boeck K, Bulteel V, Fajac I.

Eur J Pediatr. 2016 Jun;175(6):817-24. doi: 10.1007/s00431-016-2712-z. Epub 2016 Mar 15.

50.

Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.

Schaballie H, Wuyts G, Dillaerts D, Frans G, Moens L, Proesmans M, Vermeulen F, De Boeck K, Meyts I, Bossuyt X.

Clin Exp Immunol. 2016 Aug;185(2):180-9. doi: 10.1111/cei.12784. Epub 2016 May 20.

Supplemental Content

Loading ...
Support Center